Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042068
Status:
COMPLETED
Last Update Posted:
2013-11-01
First Post:
2002-07-22
Brief Title:
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Multi-center Double-Blind Randomized Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam 75 15 and 225 mg and Placebo in Patients With Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 12-week trial consisting of 5 visits 6 if follow up is needed to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis Patient will take one dose of study medication daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None